A type 2 diabetes treatment developed by Indianapolis-based Eli Lilly and Co. (NYSE: LLY) and Boehringer Ingelheim Pharmaceuticals Inc. in Connecticut has received a new approval from the U.S. Food and Drug Administration. Jardiance will now be used as a means to reduce the risk of cardiovascular death.
Lilly says Jardiance tablets are the only oral type 2 diabetes medicine shown in a clinical trial to provide life-saving cardiovascular benefits for adults with type 2 diabetes and established cardiovascular disease.
"Despite significant medical advances, approximately two out of three people with type 2 diabetes still die from cardiovascular disease. The Boehringer Ingelheim and Lilly diabetes alliance is proud to bring a groundbreaking innovation to millions of adults with type 2 diabetes and established cardiovascular disease," said Enrique Conterno, senior vice president and president, Lilly Diabetes. "As part of our ongoing commitment to people with type 2 diabetes, we are also expanding our efforts to educate the public on the link between cardiovascular disease and type 2 diabetes."
Jardiance was initially approved by the FDA in 2014 to be used along with diet and exercise to improve blood glucose levels in adults with type 2 diabetes.